Literature DB >> 17805013

Sodium channel expression within chronic multiple sclerosis plaques.

Joel A Black1, Jia Newcombe, Bruce D Trapp, Stephen G Waxman.   

Abstract

Multiple sclerosis (MS) is characterized by focal destruction of myelin sheaths, gliotic scars, and axonal damage that contributes to the accumulation of nonremitting clinical deficits. Previous studies have demonstrated coexpression of sodium channel Nav1.6 and the sodium-calcium exchanger (NCX), together with beta-amyloid precursor protein (beta-APP), a marker of axonal damage, in degenerating axons within acute MS lesions. Axonal degeneration is less frequent within chronic MS lesions than in acute plaques, although current evidence suggests that axonal loss in chronic lesions ("slow burn") is a major contributor to accumulating disability. It is not known, however, whether axonal degenerations in chronic and acute lesions share common mechanisms, despite radically differing extracellular milieus. In this study, the expression of sodium channels Nav1.2 and Nav1.6 and of NCX was examined in chronic MS plaques within the spinal cord. Nav1.2 immunostaining was not observed along demyelinated axons in chronic lesions but was expressed by scar and reactive astrocytes within the plaque. Nav1.6 immunoreactivity, which was intense at nodes of Ranvier in normal appearing white matter in the same sections, was present in approximately one-third of the demyelinated axons within these plaques in a patchy rather than continuous distribution. NCX was not detected in demyelinated axons within chronic lesions, although it was clearly present within the scar astrocytes surrounding the demyelinated axons. beta-APP accumulation occurred in a small percentage of axons within chronic lesions within the spinal cord, but beta-APP was not preferentially present in axons that expressed Nav1.6. These observations suggest that different mechanisms underlie axonal degeneration in acute and chronic MS lesions, with axonal injury occurring at sites of coexpression of Nav1.6 and NCX in acute lesions but independent of coexpression of these 2 molecules in chronic lesions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17805013     DOI: 10.1097/nen.0b013e3181462841

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  30 in total

Review 1.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

2.  Two-photon imaging of remyelination of spinal cord axons by engrafted neural precursor cells in a viral model of multiple sclerosis.

Authors:  Milton L Greenberg; Jason G Weinger; Melanie P Matheu; Kevin S Carbajal; Ian Parker; Wendy B Macklin; Thomas E Lane; Michael D Cahalan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

3.  Activity of NaV1.2 promotes neurodegeneration in an animal model of multiple sclerosis.

Authors:  Benjamin Schattling; Walid Fazeli; Birgit Engeland; Yuanyuan Liu; Holger Lerche; Dirk Isbrandt; Manuel A Friese
Journal:  JCI Insight       Date:  2016-11-17

Review 4.  Neuroprotection in multiple sclerosis: a therapeutic approach.

Authors:  Amir-Hadi Maghzi; Alireza Minagar; Emmanuelle Waubant
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

Review 5.  Roles of glial ion transporters in brain diseases.

Authors:  Shanshan Song; Lanxin Luo; Baoshan Sun; Dandan Sun
Journal:  Glia       Date:  2019-08-16       Impact factor: 7.452

Review 6.  Remyelination therapies: a new direction and challenge in multiple sclerosis.

Authors:  Jason R Plemel; Wei-Qiao Liu; V Wee Yong
Journal:  Nat Rev Drug Discov       Date:  2017-07-07       Impact factor: 84.694

Review 7.  Review: Mitochondria and disease progression in multiple sclerosis.

Authors:  D Mahad; H Lassmann; D Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12       Impact factor: 8.090

8.  Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology.

Authors:  Maya K Desai; Kelly L Sudol; Michelle C Janelsins; Michael A Mastrangelo; Maria E Frazer; William J Bowers
Journal:  Glia       Date:  2009-01-01       Impact factor: 7.452

Review 9.  Relapsing and progressive forms of multiple sclerosis: insights from pathology.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

10.  Demyelinated axons and motor function are protected by genetic deletion of perforin in a mouse model of multiple sclerosis.

Authors:  Chandra Deb; Reghann G Lafrance-Corey; Laurie Zoecklein; Louisa Papke; Moses Rodriguez; Charles L Howe
Journal:  J Neuropathol Exp Neurol       Date:  2009-09       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.